{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T02:00:37Z","timestamp":1784772037401,"version":"3.55.0"},"reference-count":73,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T00:00:00Z","timestamp":1779235200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T00:00:00Z","timestamp":1784764800000},"content-version":"vor","delay-in-days":64,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100010679","name":"Pasteur Institute of Iran","doi-asserted-by":"crossref","award":["#1203"],"award-info":[{"award-number":["#1203"]}],"id":[{"id":"10.13039\/501100010679","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-52313-0","type":"journal-article","created":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T13:06:28Z","timestamp":1779282388000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Bulky pcDNA plasmid encoding Leishmania- and Sandfly-derived antigens resulted in transient Th1 response post Leishmania major infection in BALB\/c mice"],"prefix":"10.1038","volume":"16","author":[{"given":"Negar","family":"Seyed","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamzeh","family":"Sarvnaz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Habibzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roya","family":"Yousefi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Eghbali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Gholami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahereh","family":"Taheri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sima","family":"Rafati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,20]]},"reference":[{"issue":"6","key":"52313_CR1","doi-asserted-by":"publisher","first-page":"379","DOI":"10.3347\/kjp.2022.60.6.379","volume":"60","author":"R Dinc","year":"2022","unstructured":"Dinc, R. Leishmania vaccines: The current situation with its promising aspect for the future. Korean J. Parasitol. 60(6), 379\u2013391 (2022).","journal-title":"Korean J. Parasitol."},{"key":"52313_CR2","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens13090812","author":"A Ayala","year":"2024","unstructured":"Ayala, A. et al. Advances in Leishmania vaccines: Current development and future prospects. Pathogens https:\/\/doi.org\/10.3390\/pathogens13090812 (2024).","journal-title":"Pathogens"},{"key":"52313_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.exppara.2020.107849","volume":"210","author":"A Zabala-Penafiel","year":"2020","unstructured":"Zabala-Penafiel, A. et al. The potential of live attenuated vaccines against cutaneous leishmaniasis. Exp. Parasitol. 210, 107849 (2020).","journal-title":"Exp. Parasitol."},{"key":"52313_CR4","doi-asserted-by":"publisher","DOI":"10.3390\/pathogens11040431","author":"G Volpedo","year":"2022","unstructured":"Volpedo, G. et al. The history of live attenuated centrin gene-deleted Leishmania vaccine candidates. Pathogens https:\/\/doi.org\/10.3390\/pathogens11040431 (2022).","journal-title":"Pathogens"},{"key":"52313_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms8081201","author":"NM Ikeogu","year":"2020","unstructured":"Ikeogu, N. M. et al. Leishmania immunity: Advancing immunotherapy and vaccine development. Microorganisms https:\/\/doi.org\/10.3390\/microorganisms8081201 (2020).","journal-title":"Microorganisms"},{"issue":"6","key":"52313_CR6","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1000484","volume":"5","author":"NC Peters","year":"2009","unstructured":"Peters, N. C. et al. Vector transmission of Leishmania abrogates vaccine-induced protective immunity. PLoS. Pathog. 5(6), e1000484 (2009).","journal-title":"PLoS. Pathog."},{"issue":"6","key":"52313_CR7","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1016\/j.pt.2019.04.002","volume":"35","author":"LS Hohman","year":"2019","unstructured":"Hohman, L. S. & Peters, N. C. CD4(+) T cell-mediated immunity against the phagosomal pathogen Leishmania: Implications for vaccination. Trends. Parasitol. 35(6), 423\u2013435 (2019).","journal-title":"Trends. Parasitol."},{"issue":"4","key":"52313_CR8","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006349","volume":"13","author":"ND Glennie","year":"2017","unstructured":"Glennie, N. D., Volk, S. W. & Scott, P. Skin-resident CD4+ T cells protect against Leishmania major by recruiting and activating inflammatory monocytes. PLoS. Pathog. 13(4), e1006349 (2017).","journal-title":"PLoS. Pathog."},{"issue":"12","key":"52313_CR9","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004538","volume":"10","author":"NC Peters","year":"2014","unstructured":"Peters, N. C. et al. Chronic parasitic infection maintains high frequencies of short-lived Ly6C+CD4+ effector T cells that are required for protection against re-infection. PLoS. Pathog. 10(12), e1004538 (2014).","journal-title":"PLoS. Pathog."},{"issue":"9","key":"52313_CR10","doi-asserted-by":"publisher","first-page":"1405","DOI":"10.1084\/jem.20142101","volume":"212","author":"ND Glennie","year":"2015","unstructured":"Glennie, N. D. et al. Skin-resident memory CD4+ T cells enhance protection against Leishmania major infection. J. Exp. Med. 212(9), 1405\u20131414 (2015).","journal-title":"J. Exp. Med."},{"key":"52313_CR11","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2024.1326369","volume":"15","author":"N Seyed","year":"2024","unstructured":"Seyed, N., Taheri, T. & Rafati, S. Live attenuated-nonpathogenic Leishmania and DNA structures as promising vaccine platforms against leishmaniasis: Innovations can make waves. Front. Microbiol. 15, 1326369 (2024).","journal-title":"Front. Microbiol."},{"key":"52313_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.cyto.2020.155247","volume":"147","author":"N Seyed","year":"2021","unstructured":"Seyed, N. & Rafati, S. Th1 concomitant immune response mediated by IFN-gamma protects against sand fly delivered Leishmania infection: Implications for vaccine design. Cytokine 147, 155247 (2021).","journal-title":"Cytokine"},{"issue":"10","key":"52313_CR13","doi-asserted-by":"publisher","first-page":"1497","DOI":"10.1084\/jem.194.10.1497","volume":"194","author":"Y Belkaid","year":"2001","unstructured":"Belkaid, Y. et al. The role of interleukin (IL)-10 in the persistence of Leishmania major in the skin after healing and the therapeutic potential of anti-IL-10 receptor antibody for sterile cure. J. Exp. Med. 194(10), 1497\u20131506 (2001).","journal-title":"J. Exp. Med."},{"key":"52313_CR14","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1111\/j.0105-2896.2004.00198.x","volume":"201","author":"P Scott","year":"2004","unstructured":"Scott, P. et al. The development of effector and memory T cells in cutaneous leishmaniasis: The implications for vaccine development. Immunol. Rev. 201, 318\u2013338 (2004).","journal-title":"Immunol. Rev."},{"issue":"2","key":"52313_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ab.2005.08.029","volume":"346","author":"W Yin","year":"2005","unstructured":"Yin, W., Xiang, P. & Li, Q. Investigations of the effect of DNA size in transient transfection assay using dual luciferase system. Anal. Biochem. 346(2), 289\u2013294 (2005).","journal-title":"Anal. Biochem."},{"issue":"3","key":"52313_CR16","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1074\/jbc.275.3.1625","volume":"275","author":"GL Lukacs","year":"2000","unstructured":"Lukacs, G. L. et al. Size-dependent DNA mobility in cytoplasm and nucleus. J. Biol. Chem. 275(3), 1625\u20131629 (2000).","journal-title":"J. Biol. Chem."},{"issue":"1","key":"52313_CR17","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1080\/14760584.2023.2292772","volume":"23","author":"DN Kisakov","year":"2024","unstructured":"Kisakov, D. N. et al. The use of electroporation to deliver DNA-based vaccines. Expert Rev. Vaccines. 23(1), 102\u2013123 (2024).","journal-title":"Expert Rev. Vaccines."},{"key":"52313_CR18","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines11020280","author":"C Ledesma-Feliciano","year":"2023","unstructured":"Ledesma-Feliciano, C. et al. Improved DNA vaccine delivery with needle-free injection systems. Vaccines https:\/\/doi.org\/10.3390\/vaccines11020280 (2023).","journal-title":"Vaccines"},{"issue":"8","key":"52313_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.202001812","volume":"10","author":"W Ho","year":"2021","unstructured":"Ho, W. et al. Next-generation vaccines: Nanoparticle-mediated DNA and mRNA delivery. Adv. Healthc. Mater. 10(8), e2001812 (2021).","journal-title":"Adv. Healthc. Mater."},{"key":"52313_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/pharmaceutics12010030","author":"M Lim","year":"2020","unstructured":"Lim, M. et al. Engineered nanodelivery systems to improve DNA vaccine technologies. Pharmaceutics. https:\/\/doi.org\/10.3390\/pharmaceutics12010030 (2020).","journal-title":"Pharmaceutics."},{"key":"52313_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-015-1246-y","volume":"8","author":"G Dominguez-Bernal","year":"2015","unstructured":"Dominguez-Bernal, G. et al. HisAK70: Progress towards a vaccine against different forms of leishmaniosis. Parasit. Vectors 8, 629 (2015).","journal-title":"Parasit. Vectors"},{"issue":"5","key":"52313_CR22","doi-asserted-by":"publisher","first-page":"913","DOI":"10.1038\/mt.2010.303","volume":"19","author":"C Rosazza","year":"2011","unstructured":"Rosazza, C. et al. The actin cytoskeleton has an active role in the electrotransfer of plasmid DNA in mammalian cells. Mol. Ther. 19(5), 913\u2013921 (2011).","journal-title":"Mol. Ther."},{"key":"52313_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/genes15030261","author":"C Marie","year":"2024","unstructured":"Marie, C. & Scherman, D. Antibiotic-free gene vectors: A 25-year journey to clinical trials. Genes https:\/\/doi.org\/10.3390\/genes15030261 (2024).","journal-title":"Genes"},{"issue":"1","key":"52313_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s13071-022-05437-x","volume":"15","author":"MS Lajevardi","year":"2022","unstructured":"Lajevardi, M. S. et al. Structural analysis of PpSP15 and PsSP9 sand fly salivary proteins designed with a self-cleavable linker as a live vaccine candidate against cutaneous leishmaniasis. Parasit. Vectors 15(1), 377 (2022).","journal-title":"Parasit. Vectors"},{"key":"52313_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.895234","volume":"13","author":"MS Lajevardi","year":"2022","unstructured":"Lajevardi, M. S. et al. Leishmania tarentolae as potential live vaccine co-expressing distinct salivary gland proteins against experimental cutaneous leishmaniasis in BALB\/c mice model. Front. Immunol. 13, 895234 (2022).","journal-title":"Front. Immunol."},{"issue":"5","key":"52313_CR26","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1358\/dot.2018.54.5.2807864","volume":"54","author":"F Ghaffarifar","year":"2018","unstructured":"Ghaffarifar, F. Plasmid DNA vaccines: Where are we now?. Drugs. Today. (Barc). 54(5), 315\u2013333 (2018).","journal-title":"Drugs. Today. (Barc)."},{"key":"52313_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines12010071","author":"M Kozak","year":"2024","unstructured":"Kozak, M. & Hu, J. DNA vaccines: Their formulations, engineering and delivery. Vaccines. https:\/\/doi.org\/10.3390\/vaccines12010071 (2024).","journal-title":"Vaccines."},{"issue":"4","key":"52313_CR28","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1016\/S0952-7915(00)00118-7","volume":"12","author":"S Gurunathan","year":"2000","unstructured":"Gurunathan, S. et al. DNA vaccines: A key for inducing long-term cellular immunity. Curr. Opin. Immunol. 12(4), 442\u2013447 (2000).","journal-title":"Curr. Opin. Immunol."},{"issue":"12","key":"52313_CR29","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1038\/4000","volume":"4","author":"S Gurunathan","year":"1998","unstructured":"Gurunathan, S. et al. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat. Med. 4(12), 1409\u20131415 (1998).","journal-title":"Nat. Med."},{"issue":"1","key":"52313_CR30","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1186\/1479-0556-2-17","volume":"2","author":"C Ivory","year":"2004","unstructured":"Ivory, C. & Chadee, K. DNA vaccines: Designing strategies against parasitic infections. Genet. Vaccines. Ther. 2(1), 17 (2004).","journal-title":"Genet. Vaccines. Ther."},{"issue":"2","key":"52313_CR31","doi-asserted-by":"publisher","first-page":"29","DOI":"10.18609\/vac.2024.002","volume":"3","author":"A Patel","year":"2024","unstructured":"Patel, A. Shaping immunity against infectious diseases with multivalent DNA vaccines. Vaccine. Insights. 3(2), 29\u201333 (2024).","journal-title":"Vaccine. Insights."},{"issue":"1","key":"52313_CR32","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/s00005-017-0484-4","volume":"66","author":"N Maspi","year":"2018","unstructured":"Maspi, N. et al. Comparative assessment of induced immune responses following intramuscular immunization with fusion and cocktail of LeIF, LACK and TSA genes against cutaneous leishmaniasis in BALB\/c mice. Arch. Immunol. Ther. Exp. (Warsz). 66(1), 55\u201364 (2018).","journal-title":"Arch. Immunol. Ther. Exp. (Warsz)."},{"issue":"8","key":"52313_CR33","doi-asserted-by":"publisher","first-page":"5122","DOI":"10.4049\/jimmunol.166.8.5122","volume":"166","author":"S Mendez","year":"2001","unstructured":"Mendez, S. et al. The potency and durability of DNA- and protein-based vaccines against Leishmania major evaluated using low-dose, intradermal challenge. J. Immunol. 166(8), 5122\u20135128 (2001).","journal-title":"J. Immunol."},{"issue":"31\u201332","key":"52313_CR34","doi-asserted-by":"publisher","first-page":"3702","DOI":"10.1016\/S0264-410X(02)00376-6","volume":"20","author":"S Mendez","year":"2002","unstructured":"Mendez, S. et al. Optimization of DNA vaccination against cutaneous leishmaniasis. Vaccine. 20(31\u201332), 3702\u20133708 (2002).","journal-title":"Vaccine."},{"issue":"25-26","key":"52313_CR35","doi-asserted-by":"publisher","first-page":"3369","DOI":"10.1016\/S0264-410X(01)00081-0","volume":"19","author":"S Rafati","year":"2001","unstructured":"Rafati, S. et al. A protective cocktail vaccine against murine cutaneous leishmaniasis with DNA encoding cysteine proteinases of Leishmania major. Vaccine. 19(25\u201326), 3369\u20133375 (2001).","journal-title":"Vaccine."},{"issue":"1","key":"52313_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75410-0","volume":"10","author":"P Cecilio","year":"2020","unstructured":"Cecilio, P. et al. Engineering a vector-based pan-Leishmania vaccine for humans: Proof of principle. Sci. Rep. 10(1), 18653 (2020).","journal-title":"Sci. Rep."},{"key":"52313_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.exppara.2021.108082","volume":"223","author":"AS Shermeh","year":"2021","unstructured":"Shermeh, A. S. et al. Evaluation of protection induced by in vitro maturated BMDCs presenting CD8(+) T cell stimulating peptides after a heterologous vaccination regimen in BALB\/c model against Leishmania major. Exp. Parasitol. 223, 108082 (2021).","journal-title":"Exp. Parasitol."},{"issue":"12","key":"52313_CR38","first-page":"1493","volume":"22","author":"G Salehi-Sangani","year":"2019","unstructured":"Salehi-Sangani, G. et al. Immunization against Leishmania major infection in BALB\/c mice using a subunit-based DNA vaccine derived from TSA, LmSTI1, KMP11, and LACK predominant antigens. Iran. J. Basic Med. Sci. 22(12), 1493\u20131501 (2019).","journal-title":"Iran. J. Basic Med. Sci."},{"issue":"1","key":"52313_CR39","first-page":"67","volume":"7","author":"T Miandoabi","year":"2018","unstructured":"Miandoabi, T. et al. Construction of a novel DNA vaccine candidate encoding LmSTI1-PpSP42 fusion protein from Leishmania major and Phlebotomus papatasi against cutaneous Leishmaniasis. Rep. Biochem. Mol. Biol. 7(1), 67\u201375 (2018).","journal-title":"Rep. Biochem. Mol. Biol."},{"issue":"3","key":"52313_CR40","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1111\/apm.12651","volume":"125","author":"N Maspi","year":"2017","unstructured":"Maspi, N. et al. Immunogenicity and efficacy of a bivalent DNA vaccine containing LeIF and TSA genes against murine cutaneous leishmaniasis. APMIS 125(3), 249\u2013258 (2017).","journal-title":"APMIS"},{"issue":"46","key":"52313_CR41","doi-asserted-by":"publisher","first-page":"7962","DOI":"10.1016\/j.vaccine.2007.08.023","volume":"25","author":"A Rodriguez-Cortes","year":"2007","unstructured":"Rodriguez-Cortes, A. et al. Vaccination with plasmid DNA encoding KMPII, TRYP, LACK and GP63 does not protect dogs against Leishmania infantum experimental challenge. Vaccine 25(46), 7962\u20137971 (2007).","journal-title":"Vaccine"},{"key":"52313_CR42","doi-asserted-by":"publisher","DOI":"10.3390\/microorganisms9112253","author":"L Fernandez","year":"2021","unstructured":"Fernandez, L. et al. Protective efficacy in a hamster model of a multivalent vaccine for human visceral leishmaniasis (MuLeVaClin) consisting of the KMP11, LEISH-F3+, and LJL143 antigens in virosomes, plus GLA-SE adjuvant. Microorganisms https:\/\/doi.org\/10.3390\/microorganisms9112253 (2021).","journal-title":"Microorganisms"},{"issue":"17","key":"52313_CR43","doi-asserted-by":"publisher","first-page":"3055","DOI":"10.1016\/j.vaccine.2009.10.044","volume":"28","author":"M Sedegah","year":"2010","unstructured":"Sedegah, M. et al. Vaxfectin enhances both antibody and in vitro T cell responses to each component of a 5-gene Plasmodium falciparum plasmid DNA vaccine mixture administered at low doses. Vaccine 28(17), 3055\u20133065 (2010).","journal-title":"Vaccine"},{"issue":"1","key":"52313_CR44","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1007\/s00436-023-08043-7","volume":"123","author":"A Tom","year":"2023","unstructured":"Tom, A. et al. Interactions between Leishmania parasite and sandfly: A review. Parasitol. Res. 123(1), 6 (2023).","journal-title":"Parasitol. Res."},{"issue":"22","key":"52313_CR45","doi-asserted-by":"publisher","first-page":"7845","DOI":"10.1073\/pnas.0712153105","volume":"105","author":"R Gomes","year":"2008","unstructured":"Gomes, R. et al. Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc. Natl. Acad. Sci. U. S. A. 105(22), 7845\u20137850 (2008).","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"52313_CR46","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2020.104189","volume":"80","author":"A Bordbar","year":"2020","unstructured":"Bordbar, A. et al. Bioinformatics analyses of immunogenic T-cell epitopes of LeIF and PpSP15 proteins from Leishmania major and sand fly saliva used as model antigens for the design of a multi-epitope vaccine to control leishmaniasis. Infect. Genet. Evol. 80, 104189 (2020).","journal-title":"Infect. Genet. Evol."},{"issue":"6","key":"52313_CR47","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1093\/trstmh\/traa119","volume":"115","author":"A Bordbar","year":"2021","unstructured":"Bordbar, A. et al. Cloning, high-level gene expression and bioinformatics analysis of SP15 and LeIF from Leishmania major and Iranian Phlebotomus papatasi saliva as single and novel fusion proteins: A potential vaccine candidate against leishmaniasis. Trans. R. Soc. Trop. Med. Hyg. 115(6), 699\u2013713 (2021).","journal-title":"Trans. R. Soc. Trop. Med. Hyg."},{"issue":"9","key":"52313_CR48","doi-asserted-by":"publisher","first-page":"4648","DOI":"10.1128\/IAI.00394-07","volume":"75","author":"RN Coler","year":"2007","unstructured":"Coler, R. N. et al. Leish-111f, a recombinant polyprotein vaccine that protects against visceral leishmaniasis by elicitation of CD4+ T cells. Infect. Immun. 75(9), 4648\u20134654 (2007).","journal-title":"Infect. Immun."},{"issue":"5","key":"52313_CR49","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1080\/14760584.2017.1306441","volume":"16","author":"S Scheiblhofer","year":"2017","unstructured":"Scheiblhofer, S. et al. Influence of protein fold stability on immunogenicity and its implications for vaccine design. Expert Rev. Vaccines. 16(5), 479\u2013489 (2017).","journal-title":"Expert Rev. Vaccines."},{"key":"52313_CR50","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/bs.adgen.2014.10.003","volume":"89","author":"JL Young","year":"2015","unstructured":"Young, J. L. & Dean, D. A. Electroporation-mediated gene delivery. Adv. Genet. 89, 49\u201388 (2015).","journal-title":"Adv. Genet."},{"key":"52313_CR51","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1332939","volume":"15","author":"B Lu","year":"2024","unstructured":"Lu, B. et al. The next-generation DNA vaccine platforms and delivery systems: Advances, challenges and prospects. Front. Immunol. 15, 1332939 (2024).","journal-title":"Front. Immunol."},{"issue":"3","key":"52313_CR52","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1021\/bp0600334","volume":"22","author":"JC Mohr","year":"2006","unstructured":"Mohr, J. C., de Pablo, J. J. & Palecek, S. P. Electroporation of human embryonic stem cells: Small and macromolecule loading and DNA transfection. Biotechnol. Prog. 22(3), 825\u2013834 (2006).","journal-title":"Biotechnol. Prog."},{"issue":"2","key":"52313_CR53","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1006\/mthe.2002.0526","volume":"5","author":"S Satkauskas","year":"2002","unstructured":"Satkauskas, S. et al. Mechanisms of in vivo DNA electrotransfer: Respective contributions of cell electropermeabilization and DNA electrophoresis. Mol. Ther. 5(2), 133\u2013140 (2002).","journal-title":"Mol. Ther."},{"issue":"3","key":"52313_CR54","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1016\/0014-5793(96)00590-X","volume":"389","author":"R Heller","year":"1996","unstructured":"Heller, R. et al. In vivo gene electroinjection and expression in rat liver. FEBS. Lett. 389(3), 225\u2013228 (1996).","journal-title":"FEBS. Lett."},{"issue":"4","key":"52313_CR55","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1038\/sj.gt.3300847","volume":"6","author":"I Mathiesen","year":"1999","unstructured":"Mathiesen, I. Electropermeabilization of skeletal muscle enhances gene transfer in vivo. Gene Ther. 6(4), 508\u2013514 (1999).","journal-title":"Gene Ther."},{"issue":"5","key":"52313_CR56","doi-asserted-by":"publisher","first-page":"1591","DOI":"10.1084\/jem.182.5.1591","volume":"182","author":"S Constant","year":"1995","unstructured":"Constant, S. et al. Extent of T cell receptor ligation can determine the functional differentiation of naive CD4+ T cells. J. Exp. Med. 182(5), 1591\u20131596 (1995).","journal-title":"J. Exp. Med."},{"issue":"5","key":"52313_CR57","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1084\/jem.182.5.1579","volume":"182","author":"NA Hosken","year":"1995","unstructured":"Hosken, N. A. et al. The effect of antigen dose on CD4+ T helper cell phenotype development in a T cell receptor-alpha beta-transgenic model. J. Exp. Med. 182(5), 1579\u20131584 (1995).","journal-title":"J. Exp. Med."},{"issue":"4","key":"52313_CR58","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pntd.0002174","volume":"7","author":"N Saljoughian","year":"2013","unstructured":"Saljoughian, N. et al. Development of novel prime-boost strategies based on a tri-gene fusion recombinant L. tarentolae vaccine against experimental murine visceral leishmaniasis. PLoS Negl. Trop. Dis. 7(4), e2174 (2013).","journal-title":"PLoS Negl. Trop. Dis."},{"issue":"2","key":"52313_CR59","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2021.104884","volume":"24","author":"DCO Gomes","year":"2022","unstructured":"Gomes, D. C. O. et al. Intranasal immunization with chitosan microparticles enhances LACK-DNA vaccine protection and induces specific long-lasting immunity against visceral leishmaniasis. Microbes Infect. 24(2), 104884 (2022).","journal-title":"Microbes Infect."},{"issue":"3","key":"52313_CR60","first-page":"383","volume":"15","author":"Y Taslimi","year":"2020","unstructured":"Taslimi, Y. et al. Comparison of protective potency of DNA and live vaccines expressing A2-CPA-CPB(-CTE) antigens against visceral leishmaniasis in Syrian Hamster as preliminary study. Iran. J. Parasitol. 15(3), 383\u2013392 (2020).","journal-title":"Iran. J. Parasitol."},{"key":"52313_CR61","doi-asserted-by":"publisher","first-page":"843","DOI":"10.3389\/fimmu.2018.00843","volume":"9","author":"L Fernandez","year":"2018","unstructured":"Fernandez, L. et al. Antigenicity of Leishmania-activated C-kinase antigen (LACK) in human peripheral blood mononuclear cells, and protective effect of prime-boost vaccination with pCI-neo-LACK plus attenuated LACK-expressing vaccinia viruses in hamsters. Front. Immunol. 9, 843 (2018).","journal-title":"Front. Immunol."},{"issue":"234","key":"52313_CR62","doi-asserted-by":"publisher","first-page":"234ra56","DOI":"10.1126\/scitranslmed.3008222","volume":"6","author":"S Das","year":"2014","unstructured":"Das, S. et al. Modular multiantigen T cell epitope-enriched DNA vaccine against human leishmaniasis. Sci. Transl. Med. 6(234), 234ra56 (2014).","journal-title":"Sci. Transl. Med."},{"issue":"3","key":"52313_CR63","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1016\/j.micinf.2005.10.004","volume":"8","author":"E Perez-Jimenez","year":"2006","unstructured":"Perez-Jimenez, E. et al. MVA-LACK as a safe and efficient vector for vaccination against leishmaniasis. Microbes. Infect. 8(3), 810\u2013822 (2006).","journal-title":"Microbes. Infect."},{"issue":"19","key":"52313_CR64","doi-asserted-by":"publisher","first-page":"3792","DOI":"10.1093\/nar\/27.19.3792","volume":"27","author":"P Kreiss","year":"1999","unstructured":"Kreiss, P. Plasmid DNA size does not affect the physicochemical properties of lipoplexes but modulates gene transfer efficiency. Nucleic. Acids. Res. 27(19), 3792\u20133798 (1999).","journal-title":"Nucleic. Acids. Res."},{"issue":"3","key":"52313_CR65","doi-asserted-by":"publisher","first-page":"225","DOI":"10.3390\/vaccines1030225","volume":"1","author":"JA Williams","year":"2013","unstructured":"Williams, J. A. Vector design for improved DNA vaccine efficacy, safety and production. Vaccines 1(3), 225\u2013249 (2013).","journal-title":"Vaccines"},{"issue":"3","key":"52313_CR66","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jbiotec.2010.01.025","volume":"146","author":"J Mairhofer","year":"2010","unstructured":"Mairhofer, J. et al. Marker-free plasmids for gene therapeutic applications\u2013lack of antibiotic resistance gene substantially improves the manufacturing process. J. Biotechnol. 146(3), 130\u2013137 (2010).","journal-title":"J. Biotechnol."},{"issue":"4","key":"52313_CR67","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1002\/jgm.1441","volume":"12","author":"C Marie","year":"2010","unstructured":"Marie, C. et al. pFARs, plasmids free of antibiotic resistance markers, display high-level transgene expression in muscle, skin and tumour cells. The Journal of Gene Medicine 12(4), 323\u2013332 (2010).","journal-title":"The Journal of Gene Medicine"},{"issue":"9","key":"52313_CR68","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1016\/j.tibtech.2013.06.001","volume":"31","author":"PH Oliveira","year":"2013","unstructured":"Oliveira, P. H. & Mairhofer, J. Marker-free plasmids for biotechnological applications - Implications and perspectives. Trends. Biotechnol. 31(9), 539\u2013547 (2013).","journal-title":"Trends. Biotechnol."},{"key":"52313_CR69","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10101710","author":"N Seyed","year":"2022","unstructured":"Seyed, N. et al. Antibiotic-free nanoplasmids as promising alternatives for conventional DNA vectors. Vaccines. https:\/\/doi.org\/10.3390\/vaccines10101710 (2022).","journal-title":"Vaccines."},{"key":"52313_CR70","first-page":"810","volume":"17","author":"JJ Suschak","year":"2020","unstructured":"Suschak, J. J. et al. Nanoplasmid vectors co-expressing innate immune agonists enhance DNA vaccines for venezuelan equine encephalitis virus and ebola virus. Mol. Ther. 17, 810\u2013821 (2020).","journal-title":"Mol. Ther."},{"issue":"1","key":"52313_CR71","doi-asserted-by":"publisher","first-page":"96","DOI":"10.3390\/vaccines8010096","volume":"8","author":"N Lokugamage","year":"2020","unstructured":"Lokugamage, N. et al. Antigen-based nano-immunotherapy controls parasite persistence, inflammatory and oxidative stress, and cardiac fibrosis, the hallmarks of chronic Chagas cardiomyopathy, in a mouse model of Trypanosoma cruzi infection. Vaccines. 8(1), 96 (2020).","journal-title":"Vaccines."},{"key":"52313_CR72","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.595039","volume":"11","author":"IH Chowdhury","year":"2020","unstructured":"Chowdhury, I. H., Lokugamage, N. & Garg, N. J. Experimental nanovaccine offers protection against repeat exposures to Trypanosoma cruzi through activation of polyfunctional T cell response. Front. Immunol. 11, 595039 (2020).","journal-title":"Front. Immunol."},{"key":"52313_CR73","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1213193","volume":"14","author":"A Alonso","year":"2023","unstructured":"Alonso, A. et al. A non-replicative antibiotic resistance-free DNA vaccine delivered by the intranasal route protects against canine leishmaniasis. Front. Immunol. 14, 1213193 (2023).","journal-title":"Front. Immunol."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52313-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52313-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52313-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T01:01:59Z","timestamp":1784768519000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-52313-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,20]]},"references-count":73,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["52313"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-52313-0","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,20]]},"assertion":[{"value":"28 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal study protocol was approved by the Ethics Committee of Pasteur Institute of Iran (protocol code IR.PII.REC.1399.089 on March 2021).","order":2,"name":"Ethics","label":"Institutional review board statement","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"23025"}}